Market Overview

Ra Medical Systems Names Dr. Chris Folk Vice President of Engineering


Ra Medical Systems, Inc. (NYSE:RMED), a medical device company focusing
on commercializing excimer laser systems to treat vascular and
dermatological diseases, announces the appointment of Chris Folk, PhD,
as Vice President of Engineering, effective January 13, 2020. With more
than 20 years of engineering experience primarily in medtech, Dr. Folk
has led the design, development and engineering of novel medical devices
with highly specific design requirements, leading to commercial success.
In this newly created position, Dr. Folk will report to Andrew Jackson,
Ra Medical Systems Interim CEO and CFO.

"Chris is an experienced leader, engineer and inventor who brings to Ra
Medical highly relevant expertise in engineering transformational
products and bringing game-changing medical devices to market," said Mr.
Jackson. "He has managed teams responsible for more than 20 device
development programs at firms ranging from startups to multinationals.
Notably, Chris has significant experience with catheters from his years
at Covidien Neurovascular/ev3, where he led the commercial launch of
three 510(k) catheters. We view his appointment as a significant step in
improving the design and manufacturing of the DABRA catheter to enhance
its consistency and extend its shelf life."

"I have a particular passion for innovative medical devices, whether
being developed from scratch or improving an existing design, and I see
the clear advantages of photoablation over competing technologies for
the treatment of peripheral artery disease," said Dr. Folk. "This is an
exciting opportunity for my colleagues and me to identify design and
manufacturing solutions that enhance the existing products while
concurrently developing new and next generation product offerings. I'm
delighted to join the Ra Medical team at this critical juncture as we
work toward a successful future with a differentiated product line."

Dr. Folk served for the past four years at ViaCyte, a privately held
regenerative medicine company, most recently as Engineering and Device
Manufacturing Director. He was responsible for product development
including the redesign of its lead product candidate PEC-Direct, a novel
biologic-device replacement therapy for type 1 diabetes. Prior to
ViaCyte, Dr. Folk spent three years as Device Strategy Principal
Engineer at Amgen, where he evaluated and determined unmet drug delivery
needs across the company's entire portfolio and led internal device R&D
programs to enable new routes and methods of drug delivery. Before that,
Dr. Folk served for three years as Research & Development Manager for
Covidien Neurovascular (formerly ev3) with responsibility for overseeing
cross-functional teams that successfully launched three FDA
510(k)-cleared catheters to treat ischemic stroke and aneurysms. During
his tenure, he managed the R&D team that created the first
hypotube-based catheter for neurovascular access, allowing unprecedented
torque and transmission of force.

Earlier in his career he was Senior Design and Applications
Engineer-Medical Devices for Microfabrica Corporation, a designer and
manufacturer of micromachine devices, where he was the technical manager
for NIH-funded minimally invasive heart surgery research and co-invented
the device published as the first all-micro electro-mechanical system
(MEMS) medical devices surgical tool. He began his career in the
Technical Leadership Program at General Electric, a world leader in the
design and manufacture of commercial and military jet engines, leading a
team developing the high-pressure engine core for an advanced military

Dr. Folk holds 10 issued patents with more than a dozen pending. He has
coauthored articles published in the peer-reviewed journals Circulation:
Cardiovascular Interventions, International Journal of Robotics
Research, Rapid Prototyping Journal
and Journal of American
College of Cardiology.

Dr. Folk holds a BS in Aerospace Engineering from the University of
Notre Dame, an MS in Engineering Mechanics from the University of
Cincinnati and a PhD in Aerospace Engineering from the University of
California, Los Angeles.

About Ra Medical Systems

Ra Medical Systems commercializes excimer lasers and catheters for the
treatment of vascular and dermatological diseases. In May 2017, the
DABRA laser system and single-use DABRA catheter received FDA 510(k)
clearance in the U.S. as a device for crossing chronic total occlusions,
or CTOs, in patients with symptomatic infrainguinal lower extremity
vascular disease with an intended use for ablating a channel in
occlusive peripheral vascular disease. Pharos excimer laser system is
FDA-cleared and is used as a tool in the treatment of psoriasis,
vitiligo, atopic dermatitis, and leukoderma. DABRA and Pharos are both
based on Ra Medical's core excimer laser technology platform and deploy
similar mechanisms of action. Ra Medical manufactures DABRA and Pharos
excimer lasers and catheters in a 32,000-square-foot facility located in
Carlsbad, Calif. The vertically integrated facility is ISO 13485
certified and is licensed by the state of California to manufacture
sterile, single-use catheters in controlled environments.

Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements generally relate to future events or Ra
Medical's future financial or operating performance. In some cases, you
can identify forward-looking statements because they contain words such
as "may," "will," "should," "expects," "plans," "anticipates," "could,"
"intends," "target," "projects," "contemplates," "believes,"
"estimates," "predicts," "potential" or "continue" or the negative of
these words or other similar terms or expressions that concern Ra
Medical's future expectations, strategy, plans or intentions.
Forward-looking statements in this press release include, but are not
limited to, statements regarding Ra Medical's business strategy,
including its plans to improve the consistency and shelf life of its
DABRA catheters, as well as developing new and next generation product
offerings. Ra Medical's expectations and beliefs regarding these matters
may not materialize, and actual results in future periods are subject to
risks and uncertainties that could cause actual results to differ
materially from those projected or implied by such forward-looking
statements. The potential risks and uncertainties which contribute to
the uncertain nature of these statements include, among others,
challenges inherent in developing, manufacturing, launching, marketing,
and selling new products; risks associated with acceptance of DABRA and
Pharos and procedures performed using such devices by physicians,
payors, and other third parties; development and acceptance of new
products or product enhancements; clinical and statistical verification
of the benefits achieved via the use of Ra Medical's products; the
results from our clinical trials, which may not support intended
indications or may require Ra Medical to conduct additional clinical
trials or modify ongoing clinical trials; challenges related to
commencement, patient enrollment, completion, an analysis of clinical
trials; Ra Medical's ability to manage operating expenses; Ra Medical's
ability to effectively manage inventory; Ra Medical's ability to recruit
and retain management and key personnel; Ra Medical's need to comply
with complex and evolving laws and regulations; intense and increasing
competition and consolidation in Ra Medical's industry; the impact of
rapid technological change; costs and adverse results in any ongoing or
future legal proceedings; adverse outcome of regulatory inspections; and
the other risks and uncertainties described in Ra Medical's news
releases and filings with the Securities and Exchange Commission.
Information on these and additional risks, uncertainties, and other
information affecting Ra Medical's business and operating results is
contained in Ra Medical's Annual Report on Form 10-K for the year ended
December 31, 2018 and in its other filings with the Securities and
Exchange Commission. The forward-looking statements in this press
release are based on information available to Ra Medical as of the date
hereof, and Ra Medical disclaims any obligation to update any
forward-looking statements, except as required by law.

Ra Medical investors and others should note that we announce material
information to the public about the company through a variety of means,
including our website (,
our investor relations website (,
press releases, SEC filings, and public conference calls in order to
achieve broad, non-exclusionary distribution of information to the
public and to comply with our disclosure obligations under Regulation
FD. We encourage our investors and others to monitor and review the
information we make public in these locations as such information could
be deemed to be material information. Please note that this list may be
updated from time to time.

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at